NDA 202714 · Onyx Pharms Amgen
Kyprolis
Carfilzomib · Intravenous · Proteasome Inhibitor
NovelAccelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: May 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Jul 20, 2012
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
256
37 Phase 3, 39 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Carfilzomib" as an intervention, any sponsor and status, largest first.
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsPivotal-lookingStatus unknown
University of LeedsAcademic, hospital or other
NCT01554852 · 4,420 participants · Start May 2010 · Primary completion Dec 2021
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen; Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen and 7 more · For: Multiple Myeloma
Sites: United Kingdom, United Kingdom
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaPivotal-lookingActive, not recruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT01863550 · 1,087 participants · Start Dec 6, 2013 · Primary completion Dec 31, 2026
Drug: Bortezomib; Carfilzomib and 2 more · For: Plasma Cell Myeloma
Sites: Anchorage, Alaska; Scottsdale, Arizona; Hot Springs, Arkansas · 920 sites in all
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01818752 · 955 participants · Start Jul 8, 2013 · Primary completion Jul 15, 2016
Drug: Carfilzomib; Bortezomib and 2 more · For: Multiple Myeloma
Sites: Fresno, California; Greenbrae, California; Modesto, California · 213 sites in all
- Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma PatientsPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01568866 · 929 participants · Start Jun 20, 2012 · Primary completion Nov 10, 2014
Drug: Carfilzomib; Bortezomib and 1 more · For: Multiple Myeloma
Sites: Burbank, California; La Jolla, California; Los Angeles, California · 241 sites in all
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07222761 · 915 participants (planned) · Start Jan 2, 2026 · Primary completion May 21, 2029
Drug: Linvoseltamab; Carfilzomib and 4 more · For: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sites: Atlanta, Georgia; Ann Arbor, Michigan; New York, New York · 60 sites in all
- Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple MyelomaPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01080391 · 792 participants · Start Jul 14, 2010 · Primary completion Jun 16, 2014
Drug: Dexamethasone; Lenalidomide and 1 more · For: Relapsed Multiple Myeloma
Sites: Scottsdale, Arizona; Burbank, California; Santa Rosa, California · 127 sites in all
- MInimal Residual Disease Adapted StrategyPivotal-lookingActive, not recruiting
Intergroupe Francophone du MyelomeResearch network
NCT04934475 · 791 participants · Start Dec 8, 2021 · Primary completion Sep 30, 2024
Drug: Isatuximab · For: Multiple Myeloma
Sites: Brussels, Belgium; Charleroi, Belgium; Haine-Saint-Paul, Belgium · 73 sites in all
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05572515 · 614 participants · Start Mar 29, 2023 · Primary completion Oct 13, 2025
Drug: Teclistamab; Pomalidomide and 3 more · For: Multiple Myeloma
Sites: Anchorage, Alaska; Gilbert, Arizona; Berkeley, California · 211 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kyprolis (Carfilzomib)
2024 spending
$17.7M
Beneficiaries
211
1,643 claims
Per beneficiary
$83,931
$2,009.04 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,258,003 |
| 2021 | $7,637,480 |
| 2022 | $11,995,372 |
| 2023 | $14,131,392 |
| 2024 | $17,709,545 |
Part B: Kyprolis (Carfilzomib) · HCPCS J9047
2024 spending
$397M
Beneficiaries
5,806
79,659 claims
Per beneficiary
$68,327
2024 ASP limit $48.37 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $293,479,656 |
| 2021 | $308,197,167 |
| 2022 | $366,748,276 |
| 2023 | $401,138,106 |
| 2024 | $396,705,754 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer.
Zhou C, Li C, Luo L, et al. · Cancer Cell 2024 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.
Perrot A, Lambert J, Hulin C, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, et al. · Lancet Oncol 2016 · Clinical Trial, Phase III, Comparative Study
- Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK, Rajkumar SV, Dimopoulos MA, et al. · N Engl J Med 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, et al. · Lancet 2021 · Clinical Trial, Phase III, Multicenter Study
- Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.
Perrot A, Touzeau C, Lambert J, et al. · Blood 2025 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.